Sodium–Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage‐Dependent Systemic‐Retinal Responsiveness
- 2 September 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 10992-11005
Abstract
Aims: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors exert systemic cardiometabolic, renal and vascular effects that may influence retinal health, yet whether their effects on diabetic macular oedema (DMO) are stage‐dependent remains unclear. We synthesized real‐world, interventional and mechanistic evidence on responsiveness across disease stages and retinal phenotypes. Materials and Methods: In this scoping review (PRISMA‐ScR; prospectively registered, UMIN000061304), we searched PubMed, the Cochrane Library, ClinicalTrials.gov , WHO‐ICTRP and Google Scholar for studies published from January 2014 to April 2026. Two reviewers independently screened and charted records. Heterogeneity precluded meta‐analysis, so a qualitative meta‐summary with exploratory E‐value analyses was performed. Results: Forty studies were included. Large administrative databases consistently associated SGLT2 inhibitor use with a 16%–35% lower DMO incidence (hazard ratio 0.65–0.84) and hazard ratios of 0.53–0.94 for diabetic retinopathy progression. In established DMO, observational studies reported hazard ratios of 0.39–0.81 for anti‐vascular endothelial growth factor (VEGF) injections, corticosteroid therapy and repeat vitrectomy, with the first‐vitrectomy estimate non‐significant, and attenuation in severe non‐proliferative or proliferative retinopathy. The only randomized trial (COMET) did not meet its primary endpoint; its fellow‐eye and phenotype‐specific subgroup analyses were exploratory and hypothesis‐generating. Proposed mechanisms include suppression of microglial activation, oxidative stress and angiopoietin‐2/VEGF signalling, although translational evidence remains preclinical. Conclusions: This predominantly observational evidence suggests that SGLT2 inhibitors may be associated with slower DMO disease kinetics across retinopathy stages, with reduced treatment burden most evident before severe retinopathy. Systemic SGLT2 inhibition may complement, rather than replace, anti‐VEGF therapy, which remains the cornerstone of DMO management. These findings support prospective stage‐ and phenotype‐stratified investigation.Keywords
Funding Information
- Astellas Pharma
This publication has 67 references indexed in Scilit:
- Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trialsInternational Journal of Clinical Pharmacy, 2025
- Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort StudyClinical Pharmacology & Therapeutics, 2025
- SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysisInternational Ophthalmology, 2025
- Empagliflozin and the Risk of Retinopathy in Patients With Type 2 DiabetesJAMA Ophthalmology, 2025
- Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World DataDiabetes Therapy, 2024
- Heterotypic macrophages/microglia differentially contribute to retinal ischaemia and neovascularisationDiabetologia, 2024
- Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated databaseDiabetologia, 2024
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 DiabetesJAMA Network Open, 2023
- Different retinopathy phenotypes in type 2 diabetes predict retinopathy progressionActa Diabetologica, 2020
- Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled TrialDiabetes Therapy, 2020